Literature DB >> 20485364

Nicotine addiction and nicotinic receptors: lessons from genetically modified mice.

Jean-Pierre Changeux1.   

Abstract

The past decades have seen a revolution in our understanding of brain diseases and in particular of drug addiction. This has been largely due to the identification of neurotransmitter receptors and the development of animal models, which together have enabled the investigation of brain functions from the molecular to the cognitive level. Tobacco smoking, the principal - yet avoidable - cause of lung cancer is associated with nicotine addiction. Recent studies in mice involving deletion and replacement of nicotinic acetylcholine receptor subunits have begun to identify the molecular mechanisms underlying nicotine addiction and might offer new therapeutic strategies to treat this addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485364     DOI: 10.1038/nrn2849

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  201 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

3.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

4.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

5.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

6.  Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist.

Authors:  Mark G LeSage; David Shelley; Marco Pravetoni; Paul R Pentel
Journal:  Pharmacol Biochem Behav       Date:  2012-04-04       Impact factor: 3.533

Review 7.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

8.  Glutamatergic synapse formation is promoted by α7-containing nicotinic acetylcholine receptors.

Authors:  Adrian F Lozada; Xulong Wang; Natalia V Gounko; Kerri A Massey; Jingjing Duan; Zhaoping Liu; Darwin K Berg
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

9.  Genetic variation within the Chrna7 gene modulates nicotine reward-like phenotypes in mice.

Authors:  J L Harenza; P P Muldoon; M De Biasi; M I Damaj; M F Miles
Journal:  Genes Brain Behav       Date:  2013-12-26       Impact factor: 3.449

10.  Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.

Authors:  Li-Fang Yu; J Brek Eaton; Allison Fedolak; Han-Kun Zhang; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.